INNOVATION PHARMACEUTICALS INC. Financials Innovation Pharmaceuticals Inc.
Equities
IPIX
US45782D1000
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.003 USD | +50.00% |
|
-28.57% | -38.78% |
| Feb. 01 | Innovation Pharmaceuticals Inc. Announces Resignation of Board Members | CI |
| 2023 | Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 91.5 | 38.1 | 120.8 | 93.48 | 14.64 | 10.37 |
| Enterprise Value (EV) 1 | 91.1 | 40.32 | 117.2 | 85.16 | 12.12 | 9.574 |
| P/E ratio | -5.21 x | -3.74 x | -20.2 x | -6 x | -2.22 x | -3.19 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 285,585,579 x | - | 813,271,167 x | - |
| EV / Revenue | - | - | 277,164,775 x | - | 673,326,722 x | - |
| EV / EBITDA | -6.82 x | -6.8 x | -27.5 x | -9.86 x | -1.9 x | -3.73 x |
| EV / FCF | -15 x | -7.88 x | -48 x | -9.47 x | -3.35 x | -10.3 x |
| FCF Yield | -6.66% | -12.7% | -2.08% | -10.6% | -29.8% | -9.73% |
| Price to Book | -44.7 x | -9.21 x | 91.7 x | 12.5 x | 3.3 x | 5.09 x |
| Nbr of stocks (in thousands) | 155,091 | 203,718 | 298,278 | 433,799 | 472,222 | 518,348 |
| Reference price 2 | 0.5900 | 0.1870 | 0.4050 | 0.2155 | 0.0310 | 0.0200 |
| Announcement Date | 9/11/18 | 9/30/19 | 9/14/20 | 9/27/21 | 9/28/22 | 9/28/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.423 | - | 0.018 | - |
| EBITDA 1 | -13.37 | -5.926 | -4.262 | -8.637 | -6.376 | -2.566 |
| EBIT 1 | -13.78 | -6.297 | -4.635 | -9.015 | -6.758 | -2.939 |
| Operating Margin | - | - | -1,095.74% | - | -37,544.44% | - |
| Earnings before Tax (EBT) 1 | -16.36 | -8.681 | -6.648 | -13.87 | -7.041 | -3.168 |
| Net income 1 | -16.36 | -8.681 | -6.648 | -13.87 | -7.041 | -3.168 |
| Net margin | - | - | -1,571.63% | - | -39,116.67% | - |
| EPS 2 | -0.1132 | -0.0500 | -0.0201 | -0.0359 | -0.0140 | -0.006263 |
| Free Cash Flow 1 | -6.065 | -5.114 | -2.44 | -8.995 | -3.618 | -0.9315 |
| FCF margin | - | - | -576.92% | - | -20,097.92% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/11/18 | 9/30/19 | 9/14/20 | 9/27/21 | 9/28/22 | 9/28/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 2.22 | - | - | - | - |
| Net Cash position 1 | 0.4 | - | 3.56 | 8.32 | 2.52 | 0.79 |
| Leverage (Debt/EBITDA) | - | -0.375 x | - | - | - | - |
| Free Cash Flow 1 | -6.06 | -5.11 | -2.44 | -9 | -3.62 | -0.93 |
| ROE (net income / shareholders' equity) | 905% | 276% | 499% | -309% | -115% | -93.6% |
| ROA (Net income/ Total Assets) | -110% | -74.3% | -43.6% | -47.9% | -34.2% | -20.5% |
| Assets 1 | 14.87 | 11.68 | 15.25 | 28.99 | 20.57 | 15.43 |
| Book Value Per Share 2 | -0.0100 | -0.0200 | 0 | 0.0200 | 0.0100 | 0 |
| Cash Flow per Share 2 | 0.0100 | 0 | 0.0200 | 0.0200 | 0.0100 | 0 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 9/11/18 | 9/30/19 | 9/14/20 | 9/27/21 | 9/28/22 | 9/28/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -38.78% | 1.59M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IPIX Stock
- Financials Innovation Pharmaceuticals Inc.
